McCormick, Liam M <br/><br/>
Pre-treatment with glucagon-like Peptide-1 protects against ischemic left ventricular dysfunction and stunning without a detected difference in myocardial substrate utilization.  [electronic resource] 

 -  JACC. Cardiovascular interventions  Feb 2015 
 - 292-301 p.  digital 
<br/><br/> Publication Type: Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1876-7605 
<br/><br/><label>Standard No.: </label>10.1016/j.jcin.2014.09.014  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Cardiac Catheterization<br/>Coronary Disease--surgery<br/>Female<br/>Glucagon-Like Peptide 1--administration & dosage<br/>Humans<br/>Incretins--administration & dosage<br/>Infusions, Intravenous<br/>Male<br/>Middle Aged<br/>Myocardial Ischemia--prevention & control<br/>Myocardial Stunning--prevention & control<br/>Percutaneous Coronary Intervention<br/>Treatment Outcome<br/>Ventricular Dysfunction, Left--prevention & control